The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing the first US-European pool of genomic and health data and integrating longitudinal and disease-relevant -omics data into genetic risk scores. Resulting in unprecedented potential for prediction, diagnosis, and personalised treatments for complex and rare diseases. Some of the largest biobanks in Europe and one in the USA will be securely linked and harmonized in a GDPR-compliant repository with data from more than 1.7 million genomes. INTERVENE will demonstrate the potential and benefits of powerful AI technologies on the next generation of integrative genetic scores (IGS). The clinical and economic benefits of IGS will be evaluated in key disease areas with major public health burden. Here, the newly developed IGS will be taken into clinical environment and their real-world benefits will be evaluated together with clinical experts, European patients advocate groups and medical societies and considering regulatory and ethical implications. Thus, a framework for legally and ethically responsible translation into wider clinical practice will be developed. Moreover, the partners will develop and test the role of IGS in several rare diseases as well as COVID-19 infection and severity. Importantly, to support the application of IGS via public-private partnerships including clinical practitioners, an AI-enabled federated data analysis platform, the ‘IGS4EU’ platform, will be developed for automated IGS generation and interpretation for end-users. Additionally, the IGS4EU platform will allow access of the INTERVENE data and the methodology know-how to the AI community through a competition-based benchmarking environment. In the long term, the IGS4EU platform aims to grow the disease coverage and enable a wide adoption of IGS as a gold standard in clinical research and practice.

DivAirCity “recognizes, accepts and celebratesDivAirCity is an ambitious project that aims at shifting the urban paradigm by valuing human diversity (with a focus on gender and multiculturalism) as a resource to define new urban services and models towards cultural-driven green cities. The project focuses on the Urban nexus that combines people, places, peace, economic growth, climate robustness and its impact on Air quality and decarbonization. DivAirCity, through citizen science and creativity will co-design solutions and trace their impact in a transparent and safe way. The project involves 5 EU cities representing replicable case studies: Orvieto (IT), Castellon (SP), Potsdam (D), Aarhus (DK) and Bucharest (RO). DivAirCity aims at creating different solutions: 5 Permanent Living Labs (PLL), 1 Diversity and Inclusion green city index (DIGCI), 5 Smart Cities Climate contracts (SCCo), 1 Community of Practice (CoP), 5 air pollution mitigation services, and 1 EU protocol for decarbonization diagnosis. The PLLs will implement NBS by leveraging over 55 mio budget already allocated by the cities; the DIGCI aims at assessing diversity and decarbonisation strategies; the SCCos will be delivered by co-designing new business models supported by blockchain technologies; the CoP will include the full urban ecosystem; and the air pollution new services have the ambition to enter in the market. DivAirCity presents a project beyond EU borders with an ambitious international dissemination strategy beyond Europe by the involvement of Belmont Forum CRAs, key international networks and H2020 funded projects. The consortium represents a mix of stakeholders selected out of the usual only research-focused organizations, to provide a real route-to-market, with the ambition to bring the project outcomes on the market by the end of the project. DivAirCity visibility will be enhanced by the participation of the Belgian National TV (RTBF) and its associated European and Global channels.

There are three main reasons for an immediate innovation action to apply big data technologies in Healthcare. Firstly, a Healthy nation is a Wealthy nation! An improvement in health leads to economic growth through long-term gains in human and physical capital, which ultimately raises productivity and per capita GDP. Secondly, Healthcare is one of the most expensive sectors, which accounts for 10% of the EU’s GDP continuously becoming more expensive. Thirdly, as healthcare is traditionally very conservative with adopting ICT, while big healthcare data is becoming available, the expected impact of applying big data technologies in Healthcare is enormous. BigMedilytics will transform Europe’s Healthcare sector by using state-of-the-art Big Data technologies to achieve breakthrough productivity in the sector by reducing cost, improving patient outcomes and delivering better access to healthcare facilities simultaneously, covering the entire Healthcare Continuum – from Prevention to Diagnosis, Treatment and Home Care throughout Europe. BigMedilytics produces: • A Big Data Healthcare Analytics Blueprint (defining platforms and components), which enables data integration and innovation spanning all the key players across the Healthcare Data Value Chains • Instantiations of the Blueprint which implement BigMedilytics concepts across 12 large-scale pilots accounting for an estimated 86% of deaths and 77% of the disease burden in Europe • The Best “Big Data technology and Healthcare policy” Practices related to big data technologies, new business models and European and national healthcare data policies and regulations. BigMedilytics will maximize the impact by using its Big Data Healthcare Analytics Blueprint and the Best Practices to scale-up the concepts demonstrated in the 12 pilots, to the whole Healthcare sector in Europe. It will use health records of more than 11 million patients across 8 countries and data from other sectors such as insurance and public sector.

The WideHealth Project (Widening Research on Pervasive eHealth) will enable research exchanges and training activities on the topic of Pervasive and eHealth. The overarching goal of the project is to enable a new generation of researchers in the Widening Countries to develop and adapt novel eHealth technologies exploitable in the longer run in their different healthcare contexts. Also, the project will establish a sustainable network of knowledge research and dissemination across Europe in the Pervasive Health topic. The knowledge of requirements and available technologies for eHealth will be shared and become complementary between early-stage researchers and researchers in the target institutions involved in the twinning. This will allow researchers in Widening Countries to get trained and put this knowledge to use in their own context, improving potential of digitally enabled healthcare provisioning and impacting on both preventative medicine and alternative means of treatment. In particular, the project will address the following three research aspects: (i) data driven healthcare, (ii) human factors in pervasive health, (iii) federated machine learning. Additionally, WideHealth will include training of administrative staff to improve their skills on project management and administration of research funding. This way, the project will improve management and administration skills mainly for the coordinator UKIM, which is an important barrier to participating and obtaining European funding. The consortium includes partners from three Widening countries: UKIM - the coordinator - from North Macedonia, JSI from Slovenia, and FC.ID from Portugal. FC.ID - despite being from a Widening country - is a highly ranked university, so it will have a hybrid role, both receiving and providing expertise. The leading Institutions in this project are FBK in Italy and HPI in Germany, both of them recognized with high visibility in the Pervasive Health international research community.

We live in a crucial historical moment, with tremendous challenges ahead, from climate change to the energy crisis. ELIAS emerges from the belief that AI will be a key discipline to help us tackle these challenges. At the same time, the development of AI entails deep ethical and societal concerns that need to be addressed. As for fundamental research, ELIAS will address key scientific questions about how AI can reduce computational costs, serves to model effects of policy decisions on society, and impacts individuals. ELIAS will strive for a deep integration of the fundamental research that takes place in academia and the more applications-focused research from industry. ELIAS builds on and expands the highly successful and internationally recognized European Laboratory for Learning and Intelligent Systems (ELLIS). ELIAS will further develop the excellence criteria and the pillars in ELLIS and implement actions that will support AI researchers and young talents at different stages of their careers. Furthermore, ELIAS will develop a Sciencentrepreneurship track, with the purpose of attracting and empowering talents at the interface of scientific innovation and business and establish original AI solutions that move towards a sustainable long-term future for our planet, contribute to a cohesive society, and respect individual rights. The outcome of ELIAS will be to establish Europe as a leader in AI research in which impact on the environment, society and the individual are integral considerations during development. We will measure the success of this endeavor in terms of key indicators, including the number of new cross-institutional collaborations, the number of cross-disciplinary collaborations, the number of industry-academic partnerships, publications in top conferences and journals, patents, and the number of projects that have resulted in deployed technologies.